甲胺通过调节AMPK/SIRT1通路来改善术后认知功能障碍
Peiyu Jia1, Ji Che1, Junfeng Zhang2
1Department of Pain, Huadong Hospital, Shanghai Key Laboratory of Clinical Geriatric Medicine, Fudan University, 200040 Shanghai, China.
Journal of integrative neuroscience
|September 21, 2023
概括
甲胺通过激活AMPK/SIRT1通路,改善老老鼠的术后认知功能. 这促进了自并减少了大脑微质中的氧化应激,提高了手术后的认知表现.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 老年学是指老年学的学科.
背景情况:
- 手术后认知功能障碍 (POCD) 是老年患者的一个重大并发症.
- 了解POCD背后的机制对于开发有效干预措施至关重要.
研究的目的:
- 调查甲胺改善术后认知功能障碍的机制.
- 在POCD的背景下探索甲福明对自,氧化应激和AMPK/SIRT1通路的影响.
主要方法:
- 在体内研究中使用了接受手术的斯普拉格-道利大鼠,接受了甲福明治疗,并使用莫里斯水迷宫 (MWM) 进行评估.
- 在体外研究中,BV2微质细胞用脂多糖 (LPS) 刺激,并用甲福明或化合物C治疗.
- 技术包括免疫光和西式涂抹来分析ROS,自蛋白和AMPK/SIRT1信号.
主要成果:
- 甲胺治疗前改善了老鼠的认知表现,这在MWM测试期间目标象限时间的增加表明了这一点.
- 甲胺提高了与自相关的蛋白质 (LC3) 的调节,并激活了大鼠皮层中的AMPK/SIRT1信号通路.
- 在体外,甲福明激活AMPK/SIRT1,减少微质激活,氧化应激,并促进自.
结论:
- 甲胺可以提高老老鼠的术后认知功能.
- 该机制涉及激活AMPK/SIRT1通路,从而促进自并减少皮质微中的氧化应激.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
223
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
223
Dipeptidyl Peptidase 4 Inhibitors
204
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
204
Oral Hypoglycemic Agents: Glinides
176
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
176
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
196
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
196
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Hypoglycemia and Glucagon
287
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
287


